Bifido Obtains Patent Rights for Composition Related to Rheumatoid Arthritis Improvement

[Asia Economy Reporter Minji Lee] Bifido announced on the 7th that it has obtained a patent in Korea for the Bifidobacterium pseudocatenulatum C-RAPO strain and compositions containing it, aimed at improving, preventing, or treating rheumatoid arthritis.

The company stated, "The Bifidobacterium pseudocatenulatum C-RAPO strain has shown efficacy in preventing or treating rheumatoid arthritis, confirming that it delays symptom scores, onset timing, and significantly reduces the incidence of rheumatoid arthritis," adding, "We will utilize it in clinical research for the development of rheumatoid arthritis treatments in consultation with the Ministry of Food and Drug Safety."